Lemaitre Vascular (LMAT) Misses Q4 EPS by 1c, Offers Guidance

Lemaitre Vascular (NASDAQ: LMAT) reported Q4 EPS of $0.25, $0.01 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $41 million versus the consensus estimate of $41 million.

GUIDANCE:

Lemaitre Vascular sees Q1 2023 EPS of $0.22-$0.27, versus the consensus of $0.27. Lemaitre Vascular sees Q1 2023 revenue of $42.6-45 million, versus the consensus of $41.6 million.

Lemaitre Vascular sees FY2023 EPS of $1.11-$1.20, versus the consensus of $1.19. Lemaitre Vascular sees FY2023 revenue of $174.3-178.3 million, versus the consensus of $171.4 million.

For earnings history and earnings-related data on Lemaitre Vascular (LMAT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping takeover bid as undervalued
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch